Clinical trial
A Multi-center, Randomized, Double-Blinded, Parallel and Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy in Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT06081621 is registered in ClinicalTrials.gov with Regend Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-Blinded, Parallel and Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy in Idiopathic Pulmonary Fibrosis (IPF) Patients
- Lead sponsor
- Regend Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 11, 2023
- Completion date
- March 14, 2025
- Enrollment
- 23 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.